Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board
Brian Devine, retired Chairman of PETCO, a leading pet specialty retailer, has agreed to serve as Chairman of the Business Advisory Board for Zander Therapeutics, Inc., a veterinary life sciences company and subsidiary of Entest BioMedical Inc. (OTCPINK: ENTB). "Mr. Devine's vast expertise in the animal health market, as well as his legacy of support for pet health, are an ideal match for our company," says David Koos, PhD, Chairman and CEO of Zander. "He understands the business networks we navigate, and we are honored to have our company associated with such an accomplished individual in the pet care industry."
Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies
Company sees results demonstrating a major step forward in its small molecule anti-inflammatory drug development for veterinary use. Entest BioMedical Inc.'s (OTC-PINK: ENTB) subsidiary, Zander Therapeutics, Inc. has tested compounds that act on human cells in suppressing the immune system in a small amount of dog blood. The results indicate that one of the compounds, termed Series A, suppressed the production of multiple cytokines known to be involved in inflammation by activating checkpoint NR2F6. These include IL-17a, IL-1, IL-2, TNF-α and IFN-ɣ production from activated peripheral blood mononuclear cells in a non-toxic manner.
Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
Entest BioMedical Inc.'s (PINK: ENTB) subsidiary, Zander Therapeutics Inc. ,reported that initial data from its canine study suggest that compounds currently being tested ex vivo show promise as small molecule anti-inflammatory treatments in canines. The Company is in the process of developing anti-cancer and anti-inflammatory drugs for the Canine, Feline and Equine markets. David Koos, CEO of both Entest BioMedical and Zander, stated "Finding that compounds being developed by Regen BioPharma, Inc. for modulating NR2F6 in humans appear to modulate NR2F6 in dogs is an extremely exciting development. There can be a direct crossover effect in drug development."
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is a subsidiary of Entest Group Inc. a fully reporting and trades publicly under the symbol: ETNI Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017